Elite Pharmaceuticals received FDA approval of its supplemental application for naltrexone hydrochloride in tablets of 50 mg. The therapy is used for alcohol and opioid dependence.
Published in Brief:
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||